STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy
Abstract As cancer continues to rank among the leading causes of death, the demand for novel treatments has never been higher. Immunotherapy shows promise, yet many solid tumors such as pancreatic cancer or glioblastoma remain resistant. In these, the “cold” tumor microenvironment with low immune ce...
Saved in:
| Main Authors: | Laura Gehrcken, Christophe Deben, Evelien Smits, Jonas R.M. Van Audenaerde |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | Advanced Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/advs.202500296 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The human STING agonist E7766 induces immunogenic tumor clearance, independent of tumor-intrinsic STING expression in the KRASG12D/+ Trp53−/− murine model of sarcoma
by: Karys M. Hildebrand, et al.
Published: (2025-12-01) -
Dual regulation of the cGAS-STING pathway: new targets and challenges for subtype-specific immunotherapy in breast cancer
by: Hanchu Xiong, et al.
Published: (2025-06-01) -
Metal-organic frameworks activate the cGAS-STING pathway for cancer immunotherapy
by: Shuxuan Zhu, et al.
Published: (2025-08-01) -
The activation of cGAS-STING pathway offers novel therapeutic opportunities in cancers
by: Yumin Wang, et al.
Published: (2025-06-01) -
Targeting collagen to optimize cancer immunotherapy
by: Yida Wang, et al.
Published: (2025-07-01)